189 related articles for article (PubMed ID: 31250842)
1. Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension.
Ferro Desideri L; Cutolo CA; Barra F; Ferrero S; Traverso CE
Drugs Today (Barc); 2019 Jun; 55(6):377-384. PubMed ID: 31250842
[TBL] [Abstract][Full Text] [Related]
2. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N
Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719
[TBL] [Abstract][Full Text] [Related]
3. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug.
Sharif NA
Curr Opin Pharmacol; 2024 Feb; 74():102426. PubMed ID: 38168596
[TBL] [Abstract][Full Text] [Related]
4. Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
Aihara M; Lu F; Kawata H; Iwata A; Liu K; Odani-Kawabata N; Shams NK
J Glaucoma; 2019 May; 28(5):375-385. PubMed ID: 30839416
[TBL] [Abstract][Full Text] [Related]
5. Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval.
Duggan S
Drugs; 2018 Dec; 78(18):1925-1929. PubMed ID: 30465134
[TBL] [Abstract][Full Text] [Related]
6. Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.
Aihara M; Lu F; Kawata H; Iwata A; Odani-Kawabata N
Jpn J Ophthalmol; 2021 Nov; 65(6):810-819. PubMed ID: 34495425
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study.
Nakakura S; Kanamori A; Fukuma Y; Wakabayashi S; Nagata Y; Adachi M
BMJ Open; 2021 Jan; 11(1):e040301. PubMed ID: 33514572
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan.
Miki A; Miyamoto E; Ishida N; Shii D; Hori K;
Adv Ther; 2022 May; 39(5):2085-2095. PubMed ID: 35287233
[TBL] [Abstract][Full Text] [Related]
9. Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan.
Nakazawa T; Takahashi K; Kuwayama Y; Nomura A; Shimada F
Adv Ther; 2022 Mar; 39(3):1359-1374. PubMed ID: 35072890
[TBL] [Abstract][Full Text] [Related]
10. FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma.
Sharif NA; Odani-Kawabata N; Lu F; Pinchuk L
Exp Eye Res; 2023 Apr; 229():109415. PubMed ID: 36803996
[TBL] [Abstract][Full Text] [Related]
11. Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
Fuwa M; Shimazaki A; Odani-Kawabata N; Kirihara T; Taniguchi T; Iwamura R; Yoneda K; Kato M; Morishima K; Shams NK
J Ocul Pharmacol Ther; 2021 May; 37(4):223-229. PubMed ID: 33600237
[No Abstract] [Full Text] [Related]
12. A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6).
Olander KW; Sato MA; Abrams MA; Jerkins GW; Lu F; Dinh P; Odani-Kawabata N; Chabi A; Shams NK
J Glaucoma; 2021 Jun; 30(6):473-480. PubMed ID: 33813559
[TBL] [Abstract][Full Text] [Related]
13. Changes in Prostaglandin-associated Periorbital Syndrome After Switch from Conventional Prostaglandin F2α Treatment to Omidenepag Isopropyl in 11 Consecutive Patients.
Nakakura S; Terao E; Fujisawa Y; Tabuchi H; Kiuchi Y
J Glaucoma; 2020 Apr; 29(4):326-328. PubMed ID: 31913226
[TBL] [Abstract][Full Text] [Related]
14. Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl.
Iwamura R; Tanaka M; Okanari E; Kirihara T; Odani-Kawabata N; Shams N; Yoneda K
J Med Chem; 2018 Aug; 61(15):6869-6891. PubMed ID: 29995405
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension.
Matsuo M; Matsuoka Y; Tanito M
Clin Ophthalmol; 2022; 16():1261-1279. PubMed ID: 35510270
[TBL] [Abstract][Full Text] [Related]
16. A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension.
Katsanos A; Riva I; Bozkurt B; Holló G; Quaranta L; Oddone F; Irkec M; Dutton GN; Konstas AG
Expert Opin Drug Saf; 2022 Apr; 21(4):525-539. PubMed ID: 34666576
[TBL] [Abstract][Full Text] [Related]
17. Periocular Adverse Reactions to Omidenepag Isopropyl.
Inoue K; Shiokawa M; Katakura S; Tsuruoka M; Kunimatsu-Sanuki S; Shimizu K; Ishida K; Tomita G
Am J Ophthalmol; 2022 May; 237():114-121. PubMed ID: 34942112
[TBL] [Abstract][Full Text] [Related]
18. The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice.
Esaki Y; Katsuta O; Kamio H; Noto T; Mano H; Iwamura R; Yoneda K; Odani-Kawabata N; Morishima K; Shams NK
J Ocul Pharmacol Ther; 2020 Sep; 36(7):529-533. PubMed ID: 32412835
[No Abstract] [Full Text] [Related]
19. One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma.
Inoue K; Shiokawa M; Kunimatsu-Sanuki S; Nozaki N; Shimizu K; Ishida K; Tomita G
J Ocul Pharmacol Ther; 2022 Jun; 38(5):354-358. PubMed ID: 35613407
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study).
Aihara M; Lu F; Kawata H; Tanaka Y; Yamamura K; Odani-Kawabata N; Shams NK
J Ocul Pharmacol Ther; 2019 Dec; 35(10):542-550. PubMed ID: 31674861
[No Abstract] [Full Text] [Related]
[Next] [New Search]
